当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.

Abstract：

PURPOSE:Interferon-alpha (IFN-alpha) has been shown to control symptoms, reduce platelet counts, and reduce the bone marrow megakaryocyte mass in patients with essential thrombocythemia (ET). A semisynthetic protein-polymer conjugate of IFN-alpha 2b (PEG-IFN2b) increases the serum half-life of IFN-alpha 2b. We conducted a pilot study of Peg-IFN2b in patients with ET. PATIENTS AND METHODS:Patients with a history of persistent (greater than 2 months) platelet counts >600 x 10(9)/l, with hyperplasia of bone marrow megakaryocytes in the absence of an alternate identifiable cause of thrombocytosis were eligible. Patients were required to have either thrombohemorrhagic signs and/or symptoms if previously untreated; persistence of thrombohemorrhagic signs and/or symptoms if receiving anagrelide, IFN-alpha, or hydroxyurea; or intolerance to anagrelide, IFN-alpha, or hydroxyurea. The initial PEG-IFN2b dose was from 1.5 to 4.5 micro g/kg per week subcutaneously with subsequent dose adjustments as indicated by response and adverse events. RESULTS:Eleven patients (nine female, median age 54 years, range 26-69 years) were treated. PEG-IFN2b rapidly controlled platelet counts and resolved symptoms in all patients. The median duration of PEG-IFN2b therapy on-study was 9 months (range 4-17 months). No patient had signs or symptoms of thrombosis or hemorrhage while on study. After 2 months of therapy, 10 patients (91%) were in complete remission, and 11 (100%) after 4 months. One patient discontinued therapy at 4 months because of persistent grade 3 fatigue and a second at 5 months because of anxiety and depression. CONCLUSION:PEG-IFN2b has significant activity in patients with ET. Long-term follow-up of a larger cohort of patients is needed to define its role in this disease.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Alvarado Y,Cortes J,Verstovsek S,Thomas D,Faderl S,Estrov Z,Kantarjian H,Giles FJ

doi

10.1007/s00280-002-0533-4

keywords:

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

81-6

issue

1

eissn

0344-5704

issn

1432-0843

journal_volume

51

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.

    abstract：PURPOSE:Cyclosporine A (CyA) is able to inhibit P-glycoprotein (P-gp) and to increase cytotoxicity of some anticancer drugs, including etoposide. However, the effect of CyA on the distribution of etoposide in normal tissues, which could affect their toxicity, has not been studied extensively. The purpose of this study ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-004-0784-3

    authors： Cárcel-Trullols J,Torres-Molina F,Araico A,Saadeddin A,Peris JE

    更新日期：2004-08-01 00:00:00

  • Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.

    abstract：PURPOSE:The phosphoinositide-3-kinase (PI3K) pathway is the frequently altered in human cancer. This has led to the development and study of novel PI3K inhibitors for targeted therapy and also to overcome resistance to radiotherapy. METHOD:The anti-tumour effects of PI3K inhibitors (PI-828, PI-103 and PX-866) in terms...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-018-3746-x

    authors： Aggarwal S,John S,Sapra L,Sharma SC,Das SN

    更新日期：2019-03-01 00:00:00

  • Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

    abstract：:S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-003-0617-9

    authors： Peters GJ,Noordhuis P,Van Kuilenburg AB,Schornagel JH,Gall H,Turner SL,Swart MS,Voorn D,Van Gennip AH,Wanders J,Holwerda U,Smid K,Giaccone G,Fumoleau P,Van Groeningen CJ

    更新日期：2003-07-01 00:00:00

  • A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

    abstract：PURPOSE:PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210. PATIENTS AND METHODS:Patients (Pts) with advanced cance...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-2958-1

    authors： Bruce JY,LoRusso PM,Goncalves PH,Heath EI,Sadowski E,Shalinsky DR,Zhang Y,Traynor AM,Breazna A,Ricart AD,Tortorici M,Liu G

    更新日期：2016-03-01 00:00:00

  • Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers.

    abstract：PURPOSE:Eltrombopag is indicated in patients with severe aplastic anemia (SAA) refractory to prior immunosuppressive therapy. The combination of eltrombopag and immunosuppressive therapy (such as cyclosporine) is currently being evaluated in patients with treatment-naive SAA. Cyclosporine is a human breast cancer resis...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s00280-018-3677-6

    authors： Aslanis V,Zhang J,Lomeli B,Grosch K,Ouatas T

    更新日期：2018-11-01 00:00:00

  • Ara-C affects formation of cancer cell DNA synthesome replication intermediates.

    abstract：PURPOSE:An intact and fully functional multiprotein DNA replication complex (DNA synthesome) from human as well as from murine mammary carcinoma cells was first isolated and characterized in our laboratory. The human cell synthesome supports the in vitro origin-specific simian virus 40 (SV40) DNA replication reaction i...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050046

    authors： Abdel-Aziz W,Jiang HY,Hickey RJ,Malkas LH

    更新日期：2000-01-01 00:00:00

  • A phase I study of 5-fluorouracil, leucovorin and levamisole.

    abstract：PURPOSE:The activity of 5-fluorouracil (5-FU) against colon cancer is enhanced by leucovorin and the combination of 5-FU and levamisole has activity in the adjuvant treatment of colonic malignancies. The combination of 5-FU with both leucovorin and levamisole may provide additional benefit in the treatment of colon can...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s002800050576

    authors： Cleary JF,Arzoomanian R,Alberti D,Feierabend C,Storer B,Witt P,Carbone P,Wilding G

    更新日期：1997-01-01 00:00:00

  • Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.

    abstract：PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050854

    authors： de Vos D,Slee PH,Briggs RJ,Stevenson D

    更新日期：1998-01-01 00:00:00

  • Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone.

    abstract：:This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alon...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00299870

    authors： Frustaci S,Grattoni E,Tumolo S,Crivellari D,Figoli F,Galligioni E,Veronesi A,Tirelli U,Grigoletto E

    更新日期：1986-01-01 00:00:00

  • Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

    abstract：PURPOSE:This exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of PM00104 (Zalypsis(®)) 3 mg/m(2) 1 h every 3-week intravenous infusion in patients with advanced and/or metastatic urothelial carcinoma progressing after first-line platinum-based chemotherapy. METH...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2419-7

    authors： Castellano DE,Bellmunt J,Maroto JP,Font-Pous A,Morales-Barrera R,Ghanem I,Suarez C,Martín Lorente C,Etxaniz O,Capdevila L,Coronado C,Alfaro V,Siguero M,Fernández-Teruel C,Carles J

    更新日期：2014-04-01 00:00:00

  • Effects of intravesical instillation of antitumor drugs on the induction of preneoplastic bladder lesions in rats.

    abstract：:The effects of adriamycin (ADR) and mitomycin C (MMC) as inhibitors of the development of bladder tumors in rats were studied. Six-week-old female F344 rats were divided into nine groups, five of which received 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for the first 4 weeks, no treatmen...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00256721

    authors： Ohtani M,Fukushima S,Ito N,Koiso K,Niijima T

    更新日期：1983-01-01 00:00:00

  • Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.

    abstract：PURPOSE:The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. In this phase I/II trial dexrazoxane was used as a rescue ag...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0619-7

    authors： Schroeder PE,Jensen PB,Sehested M,Hofland KF,Langer SW,Hasinoff BB

    更新日期：2003-08-01 00:00:00

  • Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.

    abstract：:The in vitro inhibitory action and metabolism of 1-beta-D-arabinofuranosylcytosine (ara-C) on human myeloid (HL-60), B-lymphoid (RPMI-8392), and T-lymphoid (Molt-3) leukemic cells was compared. Ara-C produced greater inhibitory effects in Molt-3 cells than in either HL-60 or RPMI-8392 cells. At a 48 h exposure, ara-C ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689099

    authors： Momparler RL,Onetto-Pothier N,Bouffard DY,Momparler LF

    更新日期：1990-01-01 00:00:00

  • Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.

    abstract：PURPOSE:In the treatment of head and neck malignancy, cisplatin and 5-FU have been used the most as chemotherapeutic agents. The difference in efficacies of these is unclear and controversial. To investigate more effective schedule, we analyzed the cytotoxicity in different treatment sequence with two agents in vitro a...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0658-6

    authors： Ijichi K,Adachi M,Hasegawa Y,Ogawa T,Nakamura H,Kudoh A,Yasui Y,Murakami S,Ishizaki K

    更新日期：2008-10-01 00:00:00

  • Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.

    abstract：BACKGROUND:Pre-clinical activity of SSG against melanoma and renal cancer has been identified recently although the drug's mechanism of action and activity against tumors of additional histological-types remain undefined. METHODS:The effects of SSG and SSG combination with other agents on DU145 human prostate carcinom...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0378-3

    authors： Li J,Lindner DJ,Farver C,Borden EC,Yi T

    更新日期：2007-08-01 00:00:00

  • Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients.

    abstract：PURPOSE:It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated (123)I-metaiodobenzylguanidine ((123)I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2874-9

    authors： Bulten BF,Verberne HJ,Bellersen L,Oyen WJ,Sabaté-Llobera A,Mavinkurve-Groothuis AM,Kapusta L,van Laarhoven HW,de Geus-Oei LF

    更新日期：2015-11-01 00:00:00

  • Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.

    abstract：PURPOSE:Although cisplatin is the drug of choice in treating lung cancer patients, relapse and resistance is a common drawback to its clinical effectiveness. Based on cisplatin's reported ability to interfere with numerous cellular components, including mitochondria, we probed alterations in metabolism in cisplatin-res...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2366-8

    authors： Sullivan EJ,Kurtoglu M,Brenneman R,Liu H,Lampidis TJ

    更新日期：2014-02-01 00:00:00

  • Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.

    abstract：PURPOSE:Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL. METHODS:We evaluated ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-002-0443-5

    authors： Martell RE,Peterson BL,Cohen HJ,Petros WP,Rai KR,Morrison VA,Elias L,Shepherd L,Hines J,Larson RA,Schiffer CA,Hurwitz HI

    更新日期：2002-07-01 00:00:00

  • Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.

    abstract：PURPOSE:Our aim was to develop an optimal sampling strategy for the description of the pharmacokinetics of rubitecan and its active metabolite 9-aminocamptothecin (9-AC) for use in phase II/III studies with oral rubitecan administered in a daily times five schedule. METHODS:Concentration-time data of rubitecan and 9-A...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-002-0516-5

    authors： Schoemaker NE,Mathôt RA,Schöffski P,Rosing H,Schellens JH,Beijnen JH

    更新日期：2002-12-01 00:00:00

  • Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study.

    abstract：:Hypocrellin compounds were selected as potential photosensitizers for photodynamic therapy (PDT) owing to their high quantum yields of singlet oxygen (1O2), and facility for site-directed chemical modification to enhance phototoxicity, pharmacokinetics, solubility, and light absorption in the red spectral region, amon...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050395

    authors： Estey EP,Brown K,Diwu Z,Liu J,Lown JW,Miller GG,Moore RB,Tulip J,McPhee MS

    更新日期：1996-01-01 00:00:00

  • Biological evaluation of a novel sorafenib analogue, t-CUPM.

    abstract：:Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular carcinoma. The use of structural analogues and derivatives of sorafenib has enabled the elucidation of critical targets and mechanism(s) of cell death for human cancer lines. We previously performed a st...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2626-2

    authors： Wecksler AT,Hwang SH,Liu JY,Wettersten HI,Morisseau C,Wu J,Weiss RH,Hammock BD

    更新日期：2015-01-01 00:00:00

  • Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.

    abstract：PURPOSE:Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. Resistant ovarian cancer cells often overexpress bcl-2 or p53 proteins or both. We hypothesized that arsenic compounds, such as As2O3 and As2S3, could also be active...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800100278

    authors： Du YH,Ho PC

    更新日期：2001-06-01 00:00:00

  • Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer.

    abstract：PURPOSE:To evaluate the population pharmacokinetics of pemetrexed disodium in cancer patients enrolled in four different open-label, multicenter, nonrandomized phase II studies. METHODS:Pemetrexed disodium was administered as a 10-min intravenous infusion (600 mg/m2) every 21 days. A total of four blood samples were t...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800000144

    authors： Ouellet D,Periclou AP,Johnson RD,Woodworth JR,Lalonde RL

    更新日期：2000-01-01 00:00:00

  • A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.

    abstract：BACKGROUND:We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS:Patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s00280-017-3351-4

    authors： Ueno M,Li CP,Ikeda M,Ishii H,Mizuno N,Yamaguchi T,Ioka T,Oh DY,Ichikawa W,Okusaka T,Matsuyama Y,Arai D,Chen LT,Park YS,Furuse J

    更新日期：2017-08-01 00:00:00

  • The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.

    abstract：OBJECTIVES:To assess the cardiovascular safety, tolerability and efficacy of high doses of granisetron for the treatment of nausea and vomiting in patients undergoing highly emetogenic chemotherapy. METHODS:Patients with histologically confirmed malignant disease were given an intravenous infusion of granisetron, 160 ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s00280-003-0689-6

    authors： Carmichael J,Harris AL

    更新日期：2004-02-01 00:00:00

  • Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells.

    abstract：:Unfortunately, the online published article has error in Figure 4. The correct Figure 4 is given here. ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,已发布勘误

    doi：10.1007/s00280-018-3590-z

    authors： Zhang Q,Li XT,Chen Y,Chen JQ,Zhu JY,Meng Y,Wang XQ,Li Y,Geng SS,Xie CF,Wu JS,Zhong CY,Han HY

    更新日期：2018-06-01 00:00:00

  • Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.

    abstract：:The study under discussion was a drug-drug interaction study in which the effect of ketoconazole, a potent CYP450 3A4 inhibitor, on the pharmacokinetics of Glivec (imatinib) was investigated. A total of 14 healthy subjects (13 male, 1 female) were enrolled in this study. Each subject received a single oral dose of ima...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-004-0832-z

    authors： Dutreix C,Peng B,Mehring G,Hayes M,Capdeville R,Pokorny R,Seiberling M

    更新日期：2004-10-01 00:00:00

  • Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.

    abstract：PURPOSE:To describe the natural growth of vestibular schwannoma in patients with neurofibromatosis type 2 and to predict tumor volume evolution in patients treated with bevacizumab and everolimus. METHODS:Clinical data, including longitudinal tumor volumes in patients treated by bevacizumab (n = 13), everolimus (n = 7...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3046-2

    authors： Ouerdani A,Goutagny S,Kalamarides M,Trocóniz IF,Ribba B

    更新日期：2016-06-01 00:00:00

  • Cancer chemotherapy in the elderly: a series of 51 patients aged greater than 70 years.

    abstract：:A total of 2,238 new cancer patients were treated in our institution in 1988; among the 423 (18.9%) who were greater than 70 years old, 51 underwent chemotherapy. The median age was 75.8 years, and the Karnofsky performance status (KPS) was greater than or equal to 70% for 40 patients. Malignancies were hematopoietic ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00687328

    authors： Bécouarn Y,Bui BN,Brunet R,Ravaud A

    更新日期：1991-01-01 00:00:00

  • Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age.

    abstract：PURPOSE:To evaluate the safety and efficacy of paclitaxel in elderly patients with advanced non-small-cell lung cancer (NSCLC). METHODS:We compared the toxicity, response, survival and pharmacokinetic parameters between patients between 70 and 75 years of age (elderly group) and those under 70 years of age (younger gr...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s002800000143

    authors： Nakamura Y,Sekine I,Furuse K,Saijo N

    更新日期：2000-01-01 00:00:00